Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alvogen, Inc.
Alvogen’s newly created B2B unit, Adalvo, has filed for a generic version of Takeda’s Firazyr with the EMA to enhace its peptide portfolio, which currently includes several products focused on rare diseases and diabetes. Adalvo believes it is in the first wave of applicants to submit its filing within the European Union.
Shortly after announcing the launch of Bonsity (teriparatide) in the US, Pfenex and Alvogen have picked up positive opinions from the EMA’s CHMP for their teriparatide biosimilar. However, Accord Healthcare has withdrawn its own application following concerns raised by the agency.
Pfenex marketing partner Alvogen has introduced the firm’s Bonsity version of teriparatide in the US. Representing the first Pfenex-developed product to hit the market, the launch comes as the companies are still awaiting a formal equivalence designation from the FDA.
The Alvogen group of companies has unveiled Adalvo as the new identity for its B2B unit. In an exclusive interview, general manager Anil Okay talks about the reasons behind the rebranding, what makes it unique in the B2B sphere and the significance of 2023 for Adalvo’s strategy.
- Contract Research, Toxicology Testing-CRO
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- Alvogen Korea Co., Ltd, Lotus Pharmaceuticals